Summarized by Masters of Longevity from Longevity Technology.
Interim results from a randomized, blinded canine trial test a gene therapy targeting SIRT6 and report epigenetic age changes and safety signals through six months.
Key Takeaways
- The SLAB-VET-001 study randomized 24 aged Beagles across four arms including two intravenous pDNA dose levels and an AAV8 benchmark.
- At Day 182 mean Horvath dog epigenetic clock reductions were −1.08 years in the low-dose pDNA arm and −0.48 years in the high-dose arm versus −0.07 years in control.
- Ten of 12 pDNA-treated dogs showed lower epigenetic age versus baseline and no between-group differences reached statistical significance.
